化疗提供者专科对卵巢癌结局的影响
这项回顾性队列研究纳入2015年1月至2021年12月某学术医疗机构的319例上皮性卵巢癌患者,按化疗提供者分为仅妇科肿瘤医生组、共享模式组和非妇科肿瘤医生为主组,比较总生存和无进展生存;三组间总生存和无进展生存均无显著差异。
要点
- 化疗提供者分组与总生存无显著关联:B组HR 0.94(95%CI 0.57-1.57),C组HR 1.75(95%CI 0.92-3.33)。
- 化疗提供者分组与无进展生存无显著关联:B组HR 1.20(95%CI 0.84-1.71),C组HR 1.36(95%CI 0.83-2.21)。
- 年龄较大和距妇科肿瘤医生距离增加与妇科肿瘤医生参与化疗的几率降低相关。
核心结论
- 三个指定化疗提供者分组之间无生存差异。
- 妇科肿瘤医生与肿瘤内科医生共享化疗责任可能是一种合理的照护模式,尤其对难以获得妇科肿瘤医生照护的患者。
- 妇科肿瘤医生与肿瘤内科医生之间的责任共享存在异质性,需要进一步表征。
研究设计与样本
- 回顾性队列研究,时间范围为2015年1月至2021年12月,地点为一家学术医疗机构。
- 共纳入319例上皮性卵巢癌患者。
- 按化疗提供者类型分为三组:A组仅由妇科肿瘤医生提供化疗(162例,50.8%);B组共享模式,由妇科肿瘤医生和肿瘤内科医生共同提供化疗(116例,36.4%);C组以非妇科肿瘤医生为主,由肿瘤内科医生提供化疗,妇科肿瘤医生仅在疾病进展时或更少频率参与(41例,12.9%)。
- 主要结局为总生存和无进展生存。
主要发现
- 化疗提供者分组与总生存无显著关联:B组HR 0.94(95%CI 0.57-1.57),C组HR 1.75(95%CI 0.92-3.33)。
- 化疗提供者分组与无进展生存无显著关联:B组HR 1.20(95%CI 0.84-1.71),C组HR 1.36(95%CI 0.83-2.21)。
- 年龄较大和距妇科肿瘤医生距离增加与妇科肿瘤医生参与化疗的几率降低相关。
- 各提供者分组的患者人群在人口学和临床特征上存在差异。
临床怎么用
- 共享化疗责任可能是一种合理的照护模式,尤其对难以获得妇科肿瘤医生照护的患者。
- 妇科肿瘤医生与肿瘤内科医生之间的责任共享存在异质性,需要进一步表征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Gynecologic oncologist (GO) surgeons are associated with improved outcomes for ovarian cancer (OC) patients, but evidence is limited for GOs as chemotherapy providers. We evaluated the impact of different chemotherapy provider specialties on survival in epithelial OC. METHODS: In this retrospective cohort study from January 2015 to December 2021 at an academic medical institution, we classified chemotherapy provider type into three groups: A) exclusively GO (all chemotherapy provided by a GO); B) shared model (chemotherapy provided by both a GO and a medical oncologist); and C) primarily non-GO (chemotherapy provided by a medical oncologist and a GO was only involved at times of disease progression or less frequently). Primary outcomes were overall survival (OS) and progression-free survival (PFS). RESULTS: Of 319 patients, 162 (50.8 %) were classified into chemotherapy provider type group A, 116 (36.4 %) into group B, and 41 (12.9 %) into group C. Provider group patient populations varied by demographic and clinical characteristics. Older age and increased distance to a GO were associated with decreased odds of GO chemotherapy involvement. Chemotherapy provider group was not significantly associated with OS (group B: HR 0.94 95 % CI 0.57-1.57, group C: HR 1.75 95 % CI 0.92-3.33) or PFS (group B: HR 1.20 95 % CI 0.84-1.71, group C: HR 1.36 95 % CI 0.83-2.21). CONCLUSIONS: There was no survival difference across the three designated chemotherapy provider groups. Shared chemotherapy responsibility may be a reasonable care model, especially for patients with difficulty accessing GO care. Responsibility sharing between GOs and medical oncologists is heterogenous and requires further characterization.
引用
- Wang JY, Simons EJ, Dingel A, et al. Impact of chemotherapy provider specialty on outcomes in ovarian cancer. Gynecol Oncol. 2025. PMID: 40743588. doi:10.1016/j.ygyno.2025.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。